Phlexglobal Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Phlexglobal's estimated annual revenue is currently $102.7M per year.(i)
  • Phlexglobal's estimated revenue per employee is $281,400

Employee Data

  • Phlexglobal has 365 Employees.(i)
  • Phlexglobal grew their employee count by -3% last year.

Phlexglobal's People

NameTitleEmail/Phone
1
Senior Study OwnerReveal Email/Phone
2
VP Solutions ConsultingReveal Email/Phone
3
VP - Customer Success & Professional ServicesReveal Email/Phone
4
Head Data MigrationReveal Email/Phone
5
Head Customer ServicesReveal Email/Phone
6
VP Global SalesReveal Email/Phone
7
Head Quality AssuranceReveal Email/Phone
8
VP, Cloud Engineering and OperationsReveal Email/Phone
9
Head Research And DevelopmentReveal Email/Phone
10
Human Resources DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$59.4M3348%$116MN/A
#2
$1.8M25-22%£17.5MN/A
Add Company

What Is Phlexglobal?

Established in 1997 Phlexglobal delivers a specialist comprehensive service for all administrative aspects of the clinical trial process across the pharmaceutical, biotechnology, medical device and healthcare industries. We have been pioneers at the cutting edge of study administration offering a specialist support service for all administrative and operational aspects of the clinical trial process, ranging from document management, ethics committee submission, pre and post inspection support to tracking systems support, archiving and training Phlexglobal offers a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise to deliver clinical research support solutions to meet business needs. Working in close collaboration with our clients, we combine our five core services that focus on people provision, document management and system support to deliver a range of flexible, targeted solutions. We strive to establish true partnerships with our clients, with open communication channels and clearly defined responsibilities that deliver cost-effective and efficient business solutions.

keywords:N/A

N/A

Total Funding

365

Number of Employees

$102.7M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phlexglobal News

2022-04-13 - Electronic Trial Master File Systems Market Size to grow by ...

Phlexglobal Ltd. SureClinical Inc. TransPerfect Global Inc. Veeva Systems Inc. WIRB Copernicus Group. Find additional highlights on the growth...

2021-07-28 - Global Academic Research Organization UCL Selects Phlexglobal’s Innovative eTMF Solution to Enhance TMF Compliance and Inspection-Readiness Across Entire Study Portfolio

We were quite impressed by Phlexglobal’s ability to deliver on our requirements across the board. Nancy Tappenden Project Manager University College London AMERSHAM, United Kingdom and MALVERN, Pa. (PRWEB) July 28, 2021 Phlexglobal announced today that UCL (University College London), one of t ...

2021-04-13 - New Phlexglobal Solution Offers Easy TMF Inspection of Closed Studies, Addressing a Critical Compliance Gap in the Trial Master File Lifecycle

“PhlexTMF for Viewing is an outstanding example of how Phlexglobal’s deep TMF and regulatory subject matter expertise, backed by our advanced software development team, is delivering genuine innovation." John McNeill Chief Executive Officer of Phlexglobal. AMERSHAM, England and MALVERN, Pa. (PR ...

2021-04-07 - 5 of the Top 10 Global Pharma Companies Leveraging Phlexglobal's TMF Quality Review to Reduce Time, Cost, and Potential Risks from M&A Activity

Phlexglobal’s expert TMF Quality Review solution helps companies identify what the inspectors will find, and provide pragmatic steps to achieve compliance. Karen Roy Chief Strategy Officer Phlexglobal AMERSHAM, U.K. and Malvern, Pa. (PRWEB) April 07, 2021 Phlexglobal announced today that an in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$93.6M3736%N/A
#2
$123.4M395N/AN/A
#3
$146.8M4057%N/A
#4
$83.3M40930%N/A
#5
$15M41217%N/A